MTIP
VNDA icon

Magee Thomson Investment Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Magee Thomson Investment Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1K Sell
38
-37
-49% -$527 ﹤0.01% 66
2016
Q4 		$1K Buy
75
+7
+10% +$113 ﹤0.01% 67
2016
Q3 		$1K Buy
+68
New +$915 ﹤0.01% 67

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magee Thomson Investment Partners's VNDA Position: Q1 2017 in Review

Magee Thomson Investment Partners reduced its Vanda Pharmaceuticals (VNDA) stake by 49% in Q1 2017, selling an estimated $527 and leaving 38 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #66.

Magee Thomson Investment Partners first reported a position in VNDA in Q3 2016 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

  • Magee Thomson Investment Partners held 38 shares of Vanda Pharmaceuticals worth $1K as of Q1 2017.
  • Magee Thomson Investment Partners sold 37 Vanda Pharmaceuticals shares in Q1 2017, an estimated $527.
  • Vanda Pharmaceuticals made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #66 holding.
  • Magee Thomson Investment Partners first reported a position in Vanda Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.